TriangleDigoxin (NCT06701812)
Digoxin trial for Medulloblastoma (NCT06701812). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients older than one year and younger than 30 with relapsed medulloblastoma confirmed as non-WNT, non-SHH. Prior chemotherapy and radiation are required.
The idea: oral digoxin blocks a cellular sodium-potassium pump and may trigger tumor-cell death pathways. Researchers test whether it delays progression. Dosing is continuous, once or twice daily by age, in 28-day cycles. Heart screening and measurable disease on MRI are required.
This phase 2 study plans 23 patients. Moffitt sponsors it, with Laura Metrock as investigator and Jonathan Metts as chair; 16 US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.